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Significance statement 
•• Identifies a presynaptic role for the SUMO enzyme system 
in inhibitory neurons during neuromuscular signaling.
•• Shows SUMO E2 UBC-9 localizes to GABAergic 
motor neuron presynapses and affects vesicle localization 
and muscle excitation.
•• Aids understanding of conserved UBC-9 functions in 
E:I balance, which is lost in neurological diseases.
Introduction
Excitatory to inhibitory (E:I) signaling balance is critical for 
nervous system function, and many neurological diseases, 
including epilepsy, autism, and numerous neurodegenerative 
conditions, involve E:I imbalances.1,2 Hundreds of proteins 
reside at pre- and postsynaptic sites to control the amount and 
timing of signaling at specific synapses, contributing to regula-
tion of this balance.3 A variety of post-translational modifica-
tions, including phosphorylation, ubiquitination, and 
palmitoylation tightly control the functions of synaptic pro-
teins.4-8 Many of these modifications are activity-dependent 
and serve to modulate the localization, surface expression, 
activity, and/or complex formation of synaptic proteins to 
impact synaptic vesicle release and neurotransmitter signal 
reception.4,9–15 The extent of these modifications, as well as the 
specific enzymes and target proteins involved, remain incom-
pletely understood.
Protein SUMOylation is a post-translational modifica-
tion, conserved from yeast to humans, that has emerged as a 
key regulator of neuronal and synaptic biology.8,16–18 During 
SUMOylation, proteins are modified by the covalent attach-
ment of small ubiquitin-like modifier (SUMO) polypep-
tides. These approximately 100-amino acid globular SUMO 
molecules (SUMO-1, -2/3, and -4 in humans) are similar in 
size and shape to ubiquitin and are likewise added to lysine 
residues in target proteins through the activity of a multi-
step enzymatic cascade. For SUMO, this involves activation 
of mature SUMO molecules by the E1 enzyme complex 
Aos1-Uba2 /SAE1-SAE2 followed by SUMO transfer to 
the E2 SUMO-conjugating enzyme Ubc9.16,19 Ubc9 alone, 
or in combination with any of a number of E3 ligases, medi-
ates the attachment of SUMO to the target protein.19 
Removal of SUMO peptides from substrates, as well as 
activation of immature SUMO peptides, occurs via the 
activity of SUMO isopeptidases, also known as ubiquitin-
like-specific proteases (Ulp) or sentrin-specific proteases 
(SENPs).19,20
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Originally identified for its role in regulating transcriptional 
activity and other nuclear functions, SUMOylation is now 
known to modulate the activity and localization of diverse 
cytosolic proteins, including many involved in neuronal and 
synapse physiology.8,17 Several known SUMOylated neuronal 
proteins, including huntingtin, amyloid precursor protein, 
ataxins, tau, alpha-synuclein, and BACE1, are linked to neuro-
degenerative diseases.18,21,22 SUMO-1 has also been detected 
in synaptosomes from mouse models of Alzheimer’s Disease,23 
and global SUMOylation levels are reported to be differen-
tially affected by varying levels of oxidative stress, a component 
of age- and infection-related neurodegeneration.24 Thus, the 
SUMOylation pathway has been proposed as a therapeutic tar-
get in these diseases. Biochemical studies of synaptic fractions 
from rat hippocampi indicate the presence of multiple 
SUMOylated synaptic proteins, although the identities of 
many of these remain unknown.25 Synaptic proteins shown to 
be regulated by SUMOylation, primarily at mammalian gluta-
matergic synapses, include postsynaptic scaffold proteins 
CASK and GISP,11,26 along with a number of presynaptic reg-
ulators of vesicle release.9,10,27,28 Data from other studies indi-
cate certain K+ and Na+ channels also are regulated either 
directly or indirectly via SUMOylation to promote general 
neuronal excitability, as is the AMPA receptor regulator 
Arc.16,29 Together these data demonstrate the importance of 
protein SUMOylation in controlling synaptic function at cen-
tral synapses.
Because it is the sole E2 SUMO conjugating enzyme in any 
organism, Ubc9 represents a critical component of the SUMO 
pathway. Ubc9 activity itself is regulated by SUMOylation, as 
well as by phosphorylation and acetylation.30–33 Ubc9 typically 
localizes to sites where SUMO is found,18 and organisms lack-
ing Ubc9 are not viable, suggesting the importance of 
SUMOylation in development.34–36 Multiple studies also have 
implicated Ubc9 in synaptic function and plasticity. Work in 
Drosophila uncovered a genetic requirement for Ubc9 in long 
term memory formation where it appears to act with histone 
deacetylase 4 (HDAC4).37 Studies in rat hippocampal neurons 
demonstrated the ability of Ubc9 to interact with GluR6 kain-
ate receptor subunits, which are SUMOylated following kain-
ate application to promote postsynaptic receptor internalization 
and decreased kainate-evoked currents.38 Activity-dependent 
pre- and post-synaptic localization of Ubc9, as well as other 
SUMOylation and deSUMOylation machinery, at glutamater-
gic central synapses was confirmed by several other stud-
ies.11,13–15,25 These reports underscore the importance of Ubc9 
and SUMOylation to synaptic function. However, questions as 
to whether Ubc9’s role is conserved across phylogeny and at 
diverse synapse types, including at inhibitory or peripheral syn-
apses, remain. Just one study to date has described a role for the 
SUMO system at GABAergic synapses, where it regulates the 
postsynaptic GABAA receptor scaffold protein gephyrin,39 and 
a single paper identified SUMOylation of a muscarinic 
acetylcholine receptor in heterologous cell culture.40 Moreover, 
only a few papers have explored any neuronal SUMO or Ubc9 
functions in non-mammalian organisms.37,41–45
The neuromuscular junction (NMJ) of Caenorhabditis ele-
gans is an ideal system in which to investigate the broader regu-
lation of synaptic signaling and E:I balance by the SUMO 
pathway. The body wall muscles of these microscopic round-
worms contain both excitatory inputs from cholinergic motor 
neurons that promote muscle contraction and inhibitory inputs 
from GABAergic motor neurons that promote muscle relaxa-
tion by counteracting the excitatory signals.46 Tight regulation 
of the balance of excitatory and inhibitory transmission is 
required for proper muscle contraction and movement of the 
worms. Behavioral assays, including sensitivity to paralysis 
induced by the acetylcholinesterase inhibitor, aldicarb, can be 
used to measure muscle excitation as a readout for neuromus-
cular signaling balance.47 In the presence of aldicarb, popula-
tions of worms paralyze over time. Animals carrying mutations 
that increase cholinergic signaling or decrease GABAergic 
signaling show increased paralysis relative to wild type worms, 
whereas those with decreased cholinergic or increased 
GABAergic signaling exhibit decreased paralysis.47 Numerous 
genes now known to regulate E:I signaling balance across phy-
logeny were identified based on the aldicarb phenotypes of 
mutant worms.48–50 C. elegans contain homologs of the SUMO 
E1 (AOS-1 and UBA-2 subunits) and E2 (UBC-9) enzymes, 
as well as homologs of several E3 ligases and SENPs (called 
ULPs in C. elegans).34 A single C. elegans SUMO ortholog, 
SMO-1, exists and has structural and functional similarity to 
SUMO-1 and -2 in humans. The smo-1 gene is essential and 
expressed throughout development, and animals lacking smo-1 
expression that survive due to maternal contributions are sterile 
with abnormal somatic gonads, vulvas, and germlines.51 Other 
studies have identified SUMOylated C. elegans proteins,52 and 
current estimates indicate as much as 15% to 20% of the worm 
proteome is SUMOylated at any given time, similar to esti-
mates in human cells.53,54
In this study, we set out to assess the potential requirements 
for the SUMO pathway in controlling E:I balance at the C. 
elegans NMJ. Given the localization of Ubc9 to synapses in 
mammalian neurons and the general importance of presynaptic 
protein SUMOylation for neurotransmitter release at gluta-
matergic hippocampal synapses, we hypothesized that SUMO 
pathway enzymes are required in motor neurons to maintain 
appropriate neuroromuscular E:I signaling balance and muscle 
excitation. Here, we show that the SUMO-conjugating enzyme 
UBC-9 can act in GABAergic neurons to regulate neuromus-
cular function. Overexpressed UBC-9 localized to presynaptic 
sites in GABAergic motor neurons, caused accumulation of 
GABA-containing synaptic vesicles, and increased muscle 
contraction, changes that correlated with defects in a pharma-
cologic test of GABAergic signaling. Similar results were seen 
with overexpression of the SUMO E1 subunit AOS-1, 
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supporting a role for the SUMO pathway beyond just UBC-9. 
Enhanced muscle contraction also was seen with inhibition of 
UBC-9 or AOS-1 expression, as well as with overexpression of 
a SUMO conjugation-deficient UBC-9, consistent with domi-
nant negative substrate sequestration effects. Overexpression of 
SMO-1 also modestly increased muscle excitation in a manner 
non-additive with UBC-9 overexpression, suggesting UBC-9 
and SMO-1 act in a common pathway to impact neuromuscu-
lar function and further underscoring the need for precise con-
trol of SUMO enzyme activity at this synapse. Based on these 
data, we propose that endogenous UBC-9 acts in GABAergic 
neurons, likely via a SUMO-dependent pathway, to promote 
appropriate levels GABA neurotransmitter release and prevent 
excess muscle contraction. Our results are consistent with those 
of prior studies that demonstrate the critical need for tight 
regulation of synaptic protein SUMOylation and SUMO 
enzyme function for proper synaptic signaling.
Materials and Methods
C. elegans strains
All strains were grown on nematode growth medium (NGM) 
agar plates spotted with OP50 Escherichia coli and maintained 
at 20°C according to standard protocols.55 Young adult her-
maphrodite worms were used for all experiments. Table 1 lists 
the strains used in this study.
Plasmid and strain generation
The Psnb-1::ubc-9 (pJRK22) and Psnb-1::aos-1 (pJRK23) plas-
mids were made by inserting ubc-9 or aos-1 cDNA, respec-
tively, into the PD49.26 plasmid56 containing the Psnb-1 
promoter (pFJ19). To do this, the cDNAs were amplified from 
the Vidal Orfeome clones (F29B9.6 and C08B6.9) using for-
ward and reverse primers engineered with NheI and KpnI 
restriction sites. The amplified PCR products and plasmid 
pFJ19 were digested with NheI and KpnI, then the ubc-9 or 
aos-1 cDNA was inserted into pFJ19 using T4 DNA ligase. To 
make Punc-25::aos-1 (pJRK39), pJRK23 was digested with 
SphI and BamHI to remove the Psnb-1 promoter. The Punc-
25 promoter was isolated from the pJRK8 (Punc-
25::yfp::emb-27) plasmid using the same enzymes, then ligated 
into pJRK23. The Punc-25::ubc-9 (pJRK43) and Punc-
17::ubc-9 (pJRK44) plasmids were made by inserting the Punc-
25 and Punc-17 promoters into the PD49.26 plasmid56 
containing ubc-9 cDNA. To do this, plasmids pJRK39 and 
pJRK42 (Punc-17::aos-1) were digested with SphI and BamHI 
to remove the unc-25 and unc-17 promoters, and these were 
ligated between the SphI and BamHI sites in pJRK22 follow-
ing removal of Psnb-1. To generate the Punc-25::ubc-9(C93S) 
plasmid (pJRK69), QuikChange site-directed mutagenesis 
(Agilent) was performed using primers designed to introduce a 
single basepair mutation into the ubc-9 sequence (forward 
primer: 5’-cccatcaggtaccgtgAgcttatctcttctgga-3’; reverse 
primer: 5’-tccagaagagataagcTcacggtacctgatggg-3) and per-
formed according to the manufacturer’s instructions. The 
Punc-25::gfp::smo-1(GG) (pJRK81) plasmid was made by 
inserting gfp::smo-1(GG) amplified from pJRK72 [previously 
generated from plasmid #462]57into plasmid pJRK39 using gfp 
forward and smo-1 reverse primers containing NheI and KpnI 
restriction sites, respectively. The PCR products and pJRK39 
were digested with NheI and KpnI. This removed aos-1 from 
pJRK39 and allowed for the subsequent insertion of gfp::smo-1 
into pJRK39 using T4 DNA ligase. The final pJRK81 plasmid 
was confirmed by sequencing. The Punc-25::gfp::ubc-9 
(pJRK85) plasmid was constructed in 2 steps. First, ubc-9 
cDNA containing an internal NotI restriction site at the 
N-terminus was generated via PCR amplification of ubc-9 
from pJRK43 using forward and reverse primers containing 
NheI and SacI restriction sites, respectively. Plasmid pJRK39 
and the amplified [ubc-9(NotI)] products were then digested 
with NheI and SacI to remove the aos-1 cDNA from pJRK39 
and to create restriction sites on the ubc-9(NotI) insert, and the 
two fragments were ligated to create Punc-25::ubc-9(NotI) 
(pJRK80). Second, pJRK80 and pJRK50 (Pfshr-1::gfp::fshr-1) 
were digested with NotI to remove gfp. Following heat inacti-
vation, the digested pJRK80 was treated with calf intestinal 
alkaline phosphatase. pJRK85 was created by ligating gfp into 
the NotI site in pJRK80.
Transgenic strains with panneuronal, GABAergic, or cho-
linergic neuron-specific UBC-9, UBC-9(C93S), AOS-1, or 
SMO-1(GG) overexpression were isolated following standard 
microinjection of the plasmids into the gonads of gravid N2 
adult worms as described previously and at concentrations that 
generated viable lines for each transgene.58 Psnb-1::ubc-9 
(pJRK22) and Psnb-1::aos-1 (pJRK23) were each injected at a 
concentration of 1 ng/μL, along with 10 ng/μL of Pmyo-
2::NLS::gfp (co-injection marker) to generate strains JRK71and 
JRK50, respectively. Punc-25::aos-1 (pJRK39) was injected at 
25 ng/µL, along with 10 ng/µL of Pmyo-2::NLS::gfp to gener-
ate strain JRK70. Punc-25::ubc-9 (pJRK43) was injected at a 
concentration of 10 ng/μL, along with 10 ng/μL of Pmyo-
2::NLS::gfp (co-injection marker) to generate strain JRK72 or 
with 50 ng/μL of Pttx3::dsRed to generate JRK137. Punc-
17::ubc-9 (pJRK44) was injected at 20 ng/µL, along with 10 ng/
µL of Pmyo-2::NLS::gfp to generate strain JRK102. The Punc-
25::ubc-9(C93S) (pJRK69) plasmid, Punc-25::gfp::smo-1(GG) 
(pJRK81), and Punc-25::gfp::ubc-9 (pJRK85) were each injected 
at a concentration of 10 ng/μL, along with 10 ng/μL of Pmyo-
2::NLS::gfp (co-injection marker) to generate strains JRK110, 
JRK136, and JRK134, respectively. The mock overexpression 
(OE) control strain ( JRK64) was generated by injection of 
10 ng/µL of Pmyo-2::NLS::gfp alone.
RNA interference
RNA interference (RNAi) was performed as follows using the 
feeding method in RNAi-enhanced strains. Panneuronal 
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RNAi was performed using the uIs60;nre-1(hd20) lin-
15b(hd126) strain, which expresses SID-1 RNA channels 
under a neuron-specific promoter.59,60 RNAi clones were 
obtained from a genome-wide library consisting of HT115(DE) 
E. coli carrying gene fragments for double-stranded RNA pro-
duction in the T7-tailed L4440 vector.61 Bacteria were main-
tained in the presence of 50 μg/ml ampicillin and 15 μg/ml 
tetracycline for plasmid selection.62 RNAi feeding plates were 
prepared as follows. First, 3 ml overnight cultures of bacteria 
carrying an RNAi plasmid targeting either ubc-9, aos-1, or gfp 
(negative control) were grown in Luria broth (LB) containing 
50 μg/ml ampicillin. Cultures were spotted (150 μl each) onto 
35 mm NGM agar plates containing 50 μg/ml ampicillin and 
5 mM IPTG. Plates were dried open for 2 hours, then closed 
Table 1. C. elegans strains used (*indicates additional times outcrossed to wild type).
STRAIN NUMBER GENOTyPE






JRK18 kjrEx4 (Punc-25::mcherry::snb-1; Pmyo-2::NLS::mcherry)]48
JRK24 ulp-1(ok1768)*3;ulp-3(tm1287)
JRK25 ulp-1(ok1768)*3;ulp-5(tm3071)
JRK34 uIs60 (Punc-119::yfp; Punc-119::sid-1); nre-1(hd120) lin-15(hd126)
JRK48 juIs1*1
JRK50 kjrEx12 (Psnb-1::aos-1; Pmyo-2::NLS::gfp)
JRK64 kjrEx20 (Pmyo-2::NLS::gfp)
JRK68 nuIs152*2









JRK110 kjrEx31 (Punc-25::ubc-9(C93S); Pmyo-2::NLS::gfp)]
JRK134 kjrEx34 (Punc-25::gfp::ubc-9;Pmyo-2::NLS::gfp)
JRK135 kjrEx35 (Punc-25::gfp::smo-1(GG);Pmyo-2::NLS::gfp) line #1
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and left overnight at room temperature. For panneuronal 
RNAi, a <1-generation protocol was used to avoid embryonic 
lethality caused by potential knockdown in non-neuronal tis-
sues. Worms were synchronized by bleaching gravid adults to 
hatch and recover L1s, which were then plated onto RNAi-
containing plates and grown at 20°C for 3 days. For all experi-
ments, RNAi-treated worms were grown to the young adult 
stage for use in aldicarb assays.
Aldicarb assays
NGM agar plates (35 mm) containing 1mM of aldicarb 
(Sigma-Aldrich) were prepared, then spotted with 150 μL of 
OP50 E. coli. After 1 day, approximately 20 young adult worms 
were placed on each plate in 2-minute intervals, then measured 
for total paralysis every 25 minutes. Total paralysis was defined 
as no physical movement of the worms when prodded 3 times 
with a platinum wire on the nose.47 Three plates were tested for 
each strain of worms per experiment with the experimenter 
double-blinded to genotype. The average percentage of worms 
paralyzed for each strain at each time point ± s.e.m. was calcu-
lated using Microsoft Excel. Data from a total of 3 to 15 plates 
were pooled from experiments taken at the same time intervals 
over several days. Statistical analyses were performed using 
JMP 14 software to compare the average percentages of worms 
of each strain paralyzed at the timepoint with the largest dif-
ferences for each experiment (75 or 100 minutes). All data were 
first confirmed to fall within a normal distribution using a 
Shapiro Wilk Goodness of Fit test, and equality of variances 
confirmed using the Analysis of Means (ANOM) of Variances 
test. One-way ANOVAs then were used to assess statistical 
significance of the differences in the means between groups 
(α < 0.05), followed by a Tukey’s post hoc test (α < 0.05 for 
all). Connecting letters reports, as well as p value results of 
ordered difference reports are provided.
Pentylenetetrazole assays
NGM agar plates (35 mm) containing 10 mg/ml pentylenetet-
razole (PTZ, Sigma-Aldrich) were prepared on the day of the 
experiment, allowed to dry open for 1 hour at room tempera-
ture, then spotted with 25 μL of OP50 E. coli. After 2 addi-
tional hours of drying, approximately 20 (and no less than 15) 
young adult worms were placed onto each plate in 4-minute 
intervals, then measured for anterior convulsions (“head bobs”) 
after 50 minutes.48,63 These anterior convulsions were accom-
panied by full body paralysis in some animals. Two plates were 
tested for each strain of worms per experiment with the experi-
menter double-blinded to genotype. One plate of worms of 
each genotype was also tested on plates containing 0 mg/ml 
PTZ to ensure the absence of convulsions. The average per-
centage of worms exhibiting anterior convulsions for each 
strain at each time point ± SD was calculated using Microsoft 
Excel. Data from a total of 8 to 10 plates were pooled from 
experiments taken at the same time intervals over several days. 
Statistical analyses were performed using JMP 14 software, 
with data tested for normality and equality of variances fol-
lowed by a one-way ANOVA (α < 0.05) and Tukey’s post hoc 
test (α < 0.05 for all). Connecting letters reports and p value 
results of ordered difference reports are provided.
Fluorescence microscopy
For all imaging experiments, young adult worms were immobi-
lized in 30 mg/ml 2, 3-butanedione monoxamine (Sigma-
Aldrich) for 5 to 7 minutes, then mounted on 2% agarose pads. 
Their dorsal nerve cords halfway between the vulva and the tail 
were imaged with a Leica DMLB microscope (Leica 
Microsystems) with a 100x Plan Apochromat (1.4 NA) objec-
tive equipped with green and red fluorescence filters. Images 
were captured using an Exi Aqua cooled CCD camera 
(Qimaging) with Metamorph (v7.7) software (Molecular 
Devices) as described previously.48
Quantitative imaging of GFP::SNB-1 fluorescent puncta in 
the dorsal nerve cord of worms overexpressing UBC-9 in all 
neurons (kjrEx11) or only in GABA neurons (kjrEx22) was 
performed by generating maximum intensity projections of 
z-series stacks (0.2 μm steps, 1 μm total depth). Exposure set-
tings, gain, and binning were set to fill a 12-bit dynamic range 
without saturation. These settings were identical for all images 
taken of a given fluorescent marker [i.e., GFP::SNB-1 in 
GABAergic (juIs1) or cholinergic (nuIs152) neurons] for each 
imaging set. Linescans of dorsal nerve cord puncta were gener-
ated using Metamorph (v7.1) software, and the linescan data 
were analyzed with Igor Pro (Wavemetrics) using custom writ-
ten software as previously described.64 Mercury arc lamp out-
put was normalized by measuring the intensities of 0.5 μm 
FluoSphere beads (Invitrogen Life Technologies) for each 
imaging day. Puncta intensities were calculated by dividing the 
average maximal peak intensity by the average bead intensity 
for the corresponding day. Interpunctal axonal intensities were 
similarly calculated using the average baseline fluorescence 
value within the dorsal nerve cord. Puncta widths were deter-
mined by measuring the width of each punctum at half the 
maximum peak fluorescence. Puncta densities were determined 
by quantifying the average number of puncta per 10 μm of the 
dorsal nerve cord. For all data, an average of the values for each 
worm in the data set ± s.e.m. is reported. Statistical signifi-
cance of any differences between wild type and transgenic 
strain values was determined in Igor using a one-way ANOVA 
with Tukey’s post hoc test (P ⩽ .05). Graphs of puncta intensi-
ties, interpunctal axonal fluorescence, and width show data 
normalized to wild type values. Images were cropped and set to 
matching input levels using Adobe Photoshop.
For colocalization studies, z-stacks were obtained of worms 
co-expressing mCherry::SNB-1 and GFP::UBC-9 
(kjrEx4;kjrEx34) or mCherry::SNB-1 and GFP::SMO-1 
(kjrEx4;kjrEx36) over a 2 μm total depth (0.2 μm steps), and 
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quantification of colocalization was performed using 
Metamorph 7.1. An overlaid z-stack image file was created by 
merging images taken in each of the red and green channels. 
Then, the individual plane in best focus from the merged stacks 
of both red and green channel images for each worm was 
selected for analysis. Regions containing in-focus puncta were 
selected from these single plane images, and the software’s 
linescan function was used to measure intensities across these 
portions of the image in both the red and green channels. Red 
peaks generated from the puncta were counted and recorded, 
and individual green peaks were counted and recorded sepa-
rately. Then, the regions where red and green peaks overlapped, 
indicating colocalization of the two fluorophores, were counted. 
Only regions at least 5 a.u. greater than the background inten-
sity value were considered as peaks, and red and green peaks 
that overlap at least 75% were counted for the colocalization 
analysis. The mean percentage of mCherry::SNB-1 peaks 
overlapping GFP::UBC-9 or GFP::SMO-1 and the percent-
age of GFP::UBC-9 or GFP::SMO-1 overlapping with 
mCherry::SNB-1 were determined from these counts. To con-
trol for potential bleed-through effects, worms overexpressing 
just mCherry::SNB-1 (kjrEx4), just GFP::UBC-9 (kjrEx34), 
or just GFP::SMO-1 (kjrEx36) were also imaged under both 
red and green filters using the same parameters as for the dou-
ble-transgenic strains (see Supplemental Material). Images were 
cropped and set to matching input levels for each channel using 
Adobe Photoshop.
Results
We began by assessing whether SUMO pathway enzymes were 
required for neuromuscular signaling. To do this, we tested ani-
mals with reduced expression of the genes encoding individual 
SUMO-activating subunits (AOS-1 and UBA-2), the SUMO-
conjugating enzyme (UBC-9), the E3 SUMO ligase GEI-17, 
or the SUMO proteases (ULP-1, -2, -3, -4 and -5) for paralysis 
responses induced by the acetylcholinesterase inhibitor, 
aldicarb. In these experiments reduction of gene expression was 
induced by either feeding RNAi (aos-1, uba-2, ubc-9, gei-17, 
ulp-2, and -4) or genetic mutation (ulp-1, -3, and -5). Individual 
inhibition of each of the 5 the proteases led to wild type 
aldicarb phenotypes. Wild type phenotypes were also observed 
for ulp-1;ulp-3 and ulp-1;ulp-5 genetic double mutant animals, 
potentially due to redundancy of protease function (data not 
shown). Whereas no consistent results were observed with 
knockdown of uba-2 and gei-17, modest aldicarb hypersensi-
tivity was observed with knockdown of ubc-9 or aos-1 relative 
to control-treated worms (Figure 1), indicative of increased 
muscle contraction. We also observed weak but variable 
aldicarb hypersensitivity following cell type-specific knock-
down65 of aos-1 or ubc-9 only in GABAergic but not in cholin-
ergic neurons (data not shown), suggesting that ubc-9 activity 
may be required specifically in GABAergic neurons to prevent 
excess muscle excitation. Due to the modest effects and the 
variability inherent in doing cell type-specific RNAi, we cen-
tered our subsequent investigations on the possible effects of 
SUMO enzyme overexpression on neuromuscular function, 
with a particular focus on the SUMO-conjugating enzyme 
UBC-9.
Since inhibition of SUMO enzyme expression led to 
increased muscle contraction, we expected overexpression 
would cause aldicarb resistance, consistent with decreased 
muscle contraction. However, overexpression of UBC-9 in all 
neurons or only in GABAergic neurons also led to increased 
muscle excitation, indicated by aldicarb hypersensitivity, rela-
tive to wild type worms or to negative control worms express-
ing green fluorescent protein (GFP) in pharyngeal cells as a 
co-injection marker (Figure 2a and b, Figure S1A). In contrast, 
a wild type aldicarb paralysis phenotype was observed for 
Figure 1. Knockdown of ubc-9 or aos-1 expression in neurons causes increased muscle excitation. Aldicarb assays were performed on animals 
neuronally sensitized to RNAi. Worms were fed RNAi-containing bacteria targeting gfp as a negative control, (A) ubc-9, or (B) aos-1 from the L1 stage. 
Approximately 20 young adult RNAi-treated worms per plate were exposed to 1 mM aldicarb and paralysis was measured in response to gentle prodding 
on the nose with a platinum wire. Representative assays testing 3 plates per strain are shown. Error bars denote s.e.m.
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UBC-9 overexpression exclusively in cholinergic (ACh) neu-
rons (Figure 2b, Figure S1B) Together, these data suggest that 
too much or too little UBC-9 expression in GABA neurons 
can shift the balance of neuromuscular signaling toward excita-
tion. Similar results were observed for GABA neuron-specific 
overexpression of AOS-1, suggesting the effects may be due to 
global disruption or activation of the SUMOylation pathway 
at the NMJ (Figure 2c, Figure S1C).
Given the effects of neuronal UBC-9 expression on muscle 
function and the reported roles for SUMOylation on presyn-
aptic proteins and synaptic vesicle release at other synapse 
types,10,27 we used quantitative fluorescence imaging of GFP-
tagged SNB-1/synaptobrevin, a synaptic vesicle associated 
v-SNARE protein, to test whether neuronal UBC-9 overex-
pression alters synaptic vesicle localization in GABAergic or 
cholinergic motor neurons. Previous studies have shown that 
GFP::SNB-1 expressed under cell type-specific neuronal pro-
moters marks presynaptic sites and correlates with the number 
of vesicles at synapses.66,67 For this reason, quantitative imaging 
of GFP::SNB-1 has been used extensively to measure synapse 
density, as well as serving as a readout of synaptic vesicle accu-
mulation that typically correlates with changes in synaptic 
vesicle cycling.48–50,68 Worms with increased GFP::SNB-1 
puncta intensity tend to have more vesicles clustered at syn-
apses due to decreased release, whereas decreased GFP::SNB-1 
puncta intensity (often coupled with increased interpunctal 
axonal fluorescence) correlates with increased vesicle exocytosis 
and more signaling.49,50,68,69 Compared to wild type worms, 
animals overexpressing UBC-9 in all neurons or only in GABA 
neurons had significantly brighter (~40-50%) GFP::SNB-1 
synaptic puncta in GABAergic motor neurons, as well as 
increased (30-40%) interpunctal fluorescence, compared to 
wild type animals (Figure 3a). These effects were not seen for 
GFP::SNB-1 in cholinergic motor neurons in animals with 
panneuronal or GABAergic neuron-specific overexpression of 
UBC-9 (Figure 3b), confirming the cell autonomous effect of 
UBC-9 overexpression. Similar effects on GABAergic synaptic 
vesicles were seen with AOS-1 overexpression in GABA neu-
rons (Figure 3c). Together, these results demonstrate overex-
pression of SUMO pathway enzymes causes synaptic vesicle 
accumulation in and between synapses in GABAergic neurons, 
potentially suggesting a decrease in GABA release that could 
explain the increased muscle contraction of the UBC-9 and 
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Figure 2. GABAergic neuron-specific overexpression of UBC-9 or AOS-1 causes increased muscle excitation. Aldicarb assays were performed on wild 
type (WT) animals, animals overexpressing a control plasmid (Mock OE), and animals overexpressing (A) UBC-9 in all neurons (UBC-9 Neuron OE), (B) 
UBC-9 in GABAergic neurons only (UBC-9 GABA OE), UBC-9 in cholinergic neurons only (UBC-9 ACh OE), or (C) AOS-1 in GABAergic neurons only 
(AOS-1 GABA OE). (Upper panels) Representative timecourses showing the average percentage of young adult worms paralyzed per plate (15-20 worms 
per plate, n = 3 plates) on 1 mM aldicarb. (Lower panels) Bar graphs showing cumulative data for worms paralyzed at the 75 minute timepoint (indicated by 
* in upper panels). Error bars for all graphs denote s.e.m. of the corresponding dataset. n = total # plates per strain. All bars sharing common letters (a-b) 
were determined to be statistically similar using a one-way ANOVA, followed by a Tukey’s post hoc analysis. Neuronal UBC-9 overexpression F(2, 
35) = 3.5487, P = .0395; Tukey’s post hoc WT versus Neuronal UBC-9 OE, P = .0362; Mock OE versus Neuronal UBC-9 OE, P = .1412; WT versus Mock OE, 
P = .834. GABA neuron-specific UBC-9 overexpression: F(2, 45) = 20.9361, P < .0001; Tukey’s post hoc WT versus UBC-9 GABA OE, P < .0001; Mock OE 
versus UBC-9 GABA OE, P < .0001; WT versus Mock OE, P = .6833. ACh neuron UBC-9 overexpression: F(2,24) = 11.7255, P = .0003; Tukey’s post hoc 
Mock OE versus UBC-9 ACh OE, P = .7794; Mock OE versus UBC-9 GABA OE, P = .0004; UBC-9 ACh OE versus UBC-9 GABA OE, P = .0023. GABA 
neuron-specific AOS-1 overexpression: F(2,24) = 10.093, P = .0007. Tukey’s post hoc WT versus AOS-1 GABA OE, P = .0004, Mock OE versus AOS-1 
GABA OE, P = .0736; WT versus Mock OE, P = .0947.
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Since the aldicarb and imaging results were consistent with 
decreased GABA signaling, we tested for direct effects on 
GABA-dependent behaviors by assessing the UBC-9 and 
AOS-1 GABA neuron overexpressing worms for their sensi-
tivity to the GABAA receptor antagonist, PTZ. PTZ is epilep-
togenic in mammals70,71 and induces seizures in C. elegans with 
reduced GABAergic transmission. Such seizures do not occur 
in wild type animals or in those with defects only in cholinergic 
signaling63,72 The combination of PTZ-induced seizures and 
aldicarb hypersensitivity is routinely used to identify mutants 
with GABAergic signaling defects.48,63,73 While we observed 
some background anterior “head bobbing” behavior in approxi-
mately 25% of PTZ-exposed wild type and Mock OE animals 
under our assay conditions, 95% of snb-1(md247) mutants, in 
which general synaptic transmission is reduced, showed con-
vulsions on PTZ, as expected (Figure 4)63,73,74. Although not as 
robust as the response seen with snb-1 mutants, nearly 50% of 
animals with UBC-9 GABAergic neuron overexpression and 
67% of worms with AOS-1 GABAergic neuron overexpression 
exhibited PTZ-induced convulsions (Figure 4)63. These effects 
are in line with the moderate hypersensitivity we observed with 
the UBC-9 and AOS-1 overexpressing animals in the aldicarb 
assay (Figure 2) and provide further support that animals with 
SUMO enzyme overexpression have reduced GABAergic 
signaling, likely due to decreased GABA release.73
Synaptic proteins, as well as many transcription factors and 
other nuclear proteins, are known to be SUMOylated.8,16,17 To 
test whether UBC-9 might be able to act directly at synapses, 
we imaged animals expressing either GFP::UBC-9 or the pro-
cessed form of C. elegans SUMO GFP::SMO-1(GG)57 along 
with our synaptic vesicle marker mCherry::SNB-148 and per-
formed colocalization analyses. We first observed that both 
GFP::UBC-9 and GFP::SMO-1 localized in punctate distri-
butions within the nerve cord, similar to that seen for 
mCherry::SNB-1 (Figure 5). To determine whether these 
GFP::UBC-9 and GFP::SMO-1 puncta colocalize with 
mCherry::SNB-1-labeled synapses, we isolated a single focal 
plane from z-stacks taken of the dorsal nerve cords of worms 
co-expressing mCherry::SNB-1 and either GFP::UBC-9 or 
GFP::SMO-1 and performed quantitative linescan analyses to 
determine the percentage of GFP::UBC-9 or GFP::SMO-1 
puncta that showed peak overlap with mCherry::SNB-1 
puncta. We found that 85.3 % of green GFP::UBC-9 and 87.9 
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Figure 3. Neuronal UBC-9 or AOS-1 overexpression causes synaptic vesicle accumulation at and between synaptic sites in GABAergic, but not 
cholinergic, motor neurons. Wild type (WT) worms or worms with neuronal UBC-9 or AOS-1 overexpression (Neuronal OE), GABAergic neuron-specific 
UBC-9 or AOS-1 overexpression (GABA Neuron OE) that also expressed GFP::SNB-1 in (A, C) GABAergic neurons (GABA) or in (B) cholinergic (ACh) 
neurons were imaged using a 100× objective. (Upper panels) Representative images of the dorsal nerve cords halfway between the vulva and the tail. 
(Lower panels) Quantification of puncta (synaptic) intensity, interpunctal (axonal) fluorescence, puncta width (µm), and puncta density (per 10 µm) ± s.e.m. 
Puncta intensity, interpunctal intensity, and puncta width are all shown normalized to wild type. For (A), n = 28 animals imaged for WT, n = 23 for Neuronal 
OE, n = 28 for GABA Neuron OE. For (B), n = 30 for WT, n = 25 for Neuronal OE, n = 28 for GABA Neuron OE. For (C), n = 37 for WT; n = 17 for Neuronal OE, 
n = 23 for GABA Neuron OE. young adult worms were used for all images. *P < .05, **P ⩽ .01, ***P ⩽ .001 versus WT, one-way ANOVA with Tukey’s post 
hoc test. All other comparisons P > .05.
Kreyden et al. 9
mCherry::SNB-1 peaks (Figure 5). Similarly, 84% and 83.4% 
of red mCherry::SNB-1 peaks colocalized with green 
GFP::UBC-9 and green GFP::SMO-1 peaks, respectively. 
This strong colocalization was not due to bleed-through of 
fluorophores between channels (Figure S2). Thus, while there 
was not perfect colocalization, well over three quarters of 
UBC-9 and SMO-1 puncta in the dorsal nerve cord were 
found with SNB-1-labeled synapses; likewise, the vast majority 
of SNB-1 sites contained UBC-9 and SMO-1.
Since UBC-9 and SMO-1 both localized to synapses where 
they could interact to regulate synaptic protein SUMOylation, 
we next asked whether the catalytic activity of UBC-9 was nec-
essary for the NMJ effects observed in worms overexpressing 
UBC-9. To do this, we mutated the active site of UBC-9 at 
cysteine 93, which forms a thioester bond with the activated 
SUMO75, to serine (C93S) and compared the aldicarb sensitiv-
ity of worms overexpressing wild type UBC-9 and UBC-
9(C93S) in GABAergic neurons to each other and to that of 
wild type animals. The C93S mutation has been shown to ren-
der UBC-9 catalytically inactive by preventing thioester bond 
formation with activated SUMO.76,77 Worms overexpressing 
UBC-9(C93S) in GABA neurons showed hypersensitivity to 
aldicarb-induced paralysis compared to mock overexpressing 
worms and wild type animals; this hypersensitive phenotype 
was similar to that seen with wild type UBC-9 overexpression 
(Figure 6a; Figure S3A).
Because overexpression of UBC-9 lacking its SUMO-
conjugating ability resulted in the same neuromuscular pheno-
type as did overexpression of wild type UBC-9, the active site 
of UBC-9 may not be necessary for the increased muscle con-
traction observed in UBC-9 overexpressing worms. On the 
other hand, because SUMO levels are limiting in cells.78 over-
expressing UBC-9 alone may lead to SUMO-limiting effects 
where proteins are bound to excess UBC-9 in the presence of 
too little free SUMO, causing insufficient SUMOylation and a 
UBC-9 dominant negative phenotype. To mitigate any 
SUMO-limiting effects, we co-overexpressed wild type UBC-9 
with SMO-1(GG) and again performed aldicarb assays. 
Co-overexpression of wild type UBC-9 with SMO-1 in 
GABA neurons yielded a hypersensitive phenotype relative to 
wild type worms (Figure 6b, Figure S3B). The phenotype is 
slightly, but not significantly, higher than the levels observed in 
worms overexpressing only wild type UBC-9 or only SMO-1. 
The more modest effects observed with UBC-9 overexpression 
in this experiment compared to previous experiments may be 
due to small differences in expression levels, as different lines of 
worms had to be used to accommodate the co-expression. 
Overall, however, this non-additive phenotype suggests UBC-9 
and SMO-1 may be acting in the same pathway in GABAergic 
neurons to impact muscle contraction and that ultimately 
either too much or too little SUMO enzyme activity may cause 
E:I imbalance leading to excess muscle excitation.
Discussion
SUMOylation is an essential part of synaptic transmission for 
all animals, as it controls the activity of many proteins neces-
sary for synapse formation and for pre- and post-synaptic 
function8,17. Most studies to date, however, have focused on the 
role of the SUMO pathway at excitatory glutamatergic syn-
apses. As a result, potential functions for SUMO enzymes in 
controlling signaling at different synapse types and the effects 
of SUMOylation on E:I balance remain largely unexplored, 
despite links between several known SUMOylated neuronal 
proteins and diseases involving E:I imbalances. Here, we show 
the SUMO-conjugating enzyme UBC-9 can act in inhibitory 
motor neurons, where it localizes with SUMO to presynaptic 
sites and controls synaptic vesicle localization, to modulate E:I 
balance and muscle excitation at the C. elegans NMJ.
Tight regulation of UBC-9 activity is required in 
GABAergic neurons to maintain E:I balance
Overall, our data show that misregulation of UBC-9 and 



















































Figure 4. GABAergic neuron-specific overexpression of UBC-9 or AOS-1 
causes PTZ-induced seizures, indicative of defects in GABAergic 
transmission. Wild type (WT) animals, snb-1(md427) mutants (defective 
in general synaptic transmission), animals overexpressing a control 
plasmid (Mock OE), animals overexpressing UBC-9 in GABAergic 
neurons only (UBC-9 GABA OE), or animals expressing AOS-1 in 
GABAergic neurons only (AOS-1 GABA OE) were exposed to plates 
containing 10 mg/ml PTZ for 50 minutes. Bar graphs show the mean 
percentage of young adult worms per plate exhibiting anterior 
convulsions (15-25 worms per plate). Each overlaid dot indicates the 
percentage of animals convulsing on one of the individual plates from 
which the mean was derived. n = # of plates per strain. Error bars 
denote ± SD. All bars sharing common letters (a-b) were determined to be 
statistically similar using a one-way ANOVA [F(4,41) = 36.2529, P < .0001] 
followed by a Tukey’s post hoc analysis: WT/Mock OE versus snb-1, 
P < .0001; WT versus UBC-9 GABA OE, P = .0271; Mock OE versus 
UBC-9 GABA OE, P = .0525; WT/Mock OE versus AOS-1 GABA OE 
P < .0001; UBC-9 GABA OE versus AOS-1 GABA OE, P = .0535.
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neuromuscular activity. Based on our results, we favor a model 
in which UBC-9 acts, likely via its SUMO-conjugation activ-
ity, to regulate GABAergic vesicle release and prevent excess 
muscle excitation. Several lines of evidence support our pro-
posed model. First, our over- and under-expression experi-
ments suggest tight control of neuronal UBC-9 expression is 
critical to maintain proper muscle excitation. In our initial 
screen, neuronal knockdown of the SUMO enzyme genes ubc-
9 or aos-1 led to increased muscle contraction compared to 
wild type worms (Figure 1), indicating ubc-9 and aos-1 are nec-
essary to inhibit muscle excitation. Similar increases in muscle 
contraction were seen in animals with panneuronal or 
GABAergic neuron-specific overexpression of UBC-9, but not 
with UBC-9 overexpression in cholinergic neurons (Figure 2), 
supporting a specific effect of these enzymes in GABAergic 
neurons. Second, overexpression of UBC-9 in all neurons or 
just in GABAergic neurons caused synaptic vesicle accumula-
tion at GABAergic motor neuron presynapses, as well as sensi-
tivity to the GABAA receptor antagonist, PTZ (Figures 3 and 
4). These results are consistent with decreased GABA release 
and with the increased muscle contraction observed in these 
animals.48-50 Third, both UBC-9 and SMO-1 co-localized 
with synaptic vesicle markers in GABAergic neurons (Figure 
5), implying UBC-9 may act locally at presynaptic sites where 
it could SUMOylate known or novel synaptic targets to control 
synaptic vesicle release. Fourth, the increased muscle contrac-
tion seen with overexpression of wild type UBC-9 or the 
UBC-9(C93S) mutant indicates the active site of UBC-9 is 
not necessary for the NMJ effects of UBC-9 overexpression 
(Figure 6a). Given these are overexpression experiments and 
that levels of free SUMO in cells are reportedly low,78 both 
UBC-9 variants may cause loss of function phenotypes due to 
binding and sequestration of UBC-9 targets unable to be 
SUMOylated because of catalytic inactivity [e.g., UBC-
9(C93S)] or insufficient free SUMO (e.g. wild type UBC-
9).78,79 The fact that overexpression of AOS-1 in GABAergic 
neurons also led to increased muscle contraction, synaptic vesi-
cle accumulation and PTZ-induced convulsions (Figures 2–4) 
A B
Figure 5. UBC-9 and SMO-1 localize to synaptic sites in GABAergic motor neurons. young adult worms expressing both mCherry::SNB-1 and either (A) 
GFP::UBC-9 or (B) GFP::SMO-1 in GABAergic motor neurons were immobilized and imaged on a Leica DMLB fluorescence microscope at 100X 
magnification. (Upper panels) Representative single plane images from 2 µm total depth z-stacks taken of the dorsal nerve cords where neuromuscular 
synapses are found. White arrowheads mark sites of colocalization; yellow arrows denote sites with only one marker localized. (Lower panels) 
Quantification of the mean percentage of colocalization of peaks of mCherry::SNB-1 colocalization with GFP::UBC-9 and GFP::SMO-1 ± SD generated 
from linescans of the dorsal nerve cords. Box and whisker plots show the minima and maxima (whiskers), as well as the first and third quartiles of data 
(boxes), divided by the median line. The “X” denotes the mean value of the data set, and circles show individual data points. (n = 27 UBC-9/SNB-1 and 
n = 26 SMO-1/SNB-1 animals imaged).
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further supports this model in which SUMO:enzyme stoichi-
ometry is disrupted in the overexpression context rather than a 
specific SUMO-independent effect of UBC-9. Fifth and 
finally, the non-additive increases in muscle excitation caused 
by UBC-9 and SMO-1 co-overexpression suggest these pro-
teins act in the same pathway to impact neuromuscular func-
tion and that too much, as well as too little, SUMOylation can 
increase signaling for muscle contraction (Figure 6b). Together, 
these findings support a role for UBC-9 in GABAergic neu-
rons to control GABA release, prevent excess muscle contrac-
tion, and maintain E:I balance. While this is the first study 
implicating UBC-9 and the SUMO system at inhibitory pre-
synapses, recent work showed GABAergic neuron-specific 
effects of several ubiquitin ligase enzymes in neuromuscular 
regulation,48,80,81 highlighting the importance of related pro-
tein modification systems in inhibitory neuronal signaling.
How likely is it that GABAergic neurons are the primary 
site of UBC-9 action at the NMJ? Our data suggest UBC-9 is 
necessary and sufficient in all neurons, and specifically in 
GABAergic neurons, to control muscle excitation, where it is 
also sufficient to cause PTZ-induced seizures and to alter syn-
aptic vesicle localization in a manner consistent with decreased 
GABA release (Figures 1, 2, 3, 4, 6). While is it possible the 
knockdown phenotype we observed is due to inhibition of ubc-
9 or aos-1 in non-neuronal cells, the strain used for the RNAi 
experiments expresses high levels of SID-1 dsRNA channels in 
neurons, which biases RNAi effects toward these cells.59 When 
examining specific neuronal subtypes relevant for NMJ con-
trol, we found that overexpression of UBC-9 in GABAergic 
neurons increased muscle excitation, whereas there was no 
effect of UBC-9 overexpression in cholinergic neurons. The 
reason for this GABAergic neuron expression effect remains 
unknown; however, our data do not rule out a role in excitatory 
cells. One possible explanation for the cell type-specific effects 
is that differing levels of UBC-9 expression are achieved with 
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Figure 6. UBC-9 overexpression effects on NMJ signaling are independent of UBC-9 catalytic activity and are non-additive with co-expression of SMO-1. 
Aldicarb assays were performed on wild type (WT) animals, on animals overexpressing a control plasmid (Mock OE), and animals overexpressing (A) 
UBC-9 or UBC-9(C93S) or (B) UBC-9, SMO-1(GG), or UBC-9+SMO-1(GG) in GABA neurons. (Upper panels) Representative timecourses showing the 
average percentage of young adult worms paralyzed per plate (15-20 worms per plate, n = 3 plates) on 1 mM aldicarb. (Lower panels) Bar graphs 
quantifying cumulative data for worms paralyzed at a single timepoint (indicated by * in upper panels). Error bars for all graphs denote s.e.m. of the 
corresponding dataset. n = total # plates per strain. All bars sharing common letters (a-b) were determined to be statistically similar using a one-way 
ANOVA, followed by a Tukey’s post hoc analysis. (A) ANOVA: F(3,32) = 17.2912, P < .0001; Tukey’s post hoc WT versus UBC-9(C93S), P < .0001; Mock 
OE versus UBC-9(C93S), P < .0001; WT versus UBC-9, P = .0002; Mock OE versus UBC-9, P = .0002; UBC-9 versus UBC-9(C93S), P = .9184; WT versus 
Mock OE, P = .4934). (B) ANOVA: F(3,40) = 8.4909, P = .0002; Tukey’s post hoc WT versus UBC-9+SMO-1, P < .0001; UBC-9 versus UBC-9+SMO-1, 
P = .0589; SMO-1 versus UBC-9+SMO-1, P = .2976.
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overexpression studies. Similar variability in expression also 
could explain the lack of ubc-9 knockdown effects in animals 
engineered to allow RNAi only in cholinergic versus only in 
GABAergic neurons in our preliminary studies (data not 
shown). Alternatively, it is possible there is more compensation 
for effects on neuromuscular transmission in the cholinergic 
neurons. Unlike GABAergic neurons, which only synapse with 
postsynaptic muscle, cholinergic motor neurons directly signal 
to both GABAergic motor neurons and to muscle cells to 
maintain E:I balance.82 Similar GABAergic neuron-specific 
effects to those we observed were seen with inhibition of the 
anaphase promoting complex and EEL-1 ubiquitin ligases, the 
F-box protein MEC-15 FBXW9, as well as the cell adhesion 
molecule CASY-1, in prior studies at this synapse.48,80,81,83 
These collective results demonstrate GABAergic neuron-spe-
cific regulation is possible, and even common, and that the 
aldicarb paralysis assay may be particularly sensitive to defects 
in inhibitory neurons.50
We found that GABAergic neuron-specific overexpression 
not only of wild type UBC-9 but also the C93S mutant 
increased muscle excitation (Figure 6a), suggesting UBC-9’s 
effects may be independent of its catalytic activity; however, 
because of the overexpression context, we believe this does not 
necessarily reflect a SUMOylation-independent role for 
endogenous UBC-9 at this synapse. Rather, the increased mus-
cle contraction seen with overexpression of either wild type 
UBC-9 or UBC-9(C93S) may actually be due to a loss of func-
tion of the enzyme in both cases due to sequestration of UBC-9 
targets unable to be SUMOylated. In support of this idea, a 
yeast two-hybrid assay performed by Eloranta and Hurst 
(2002) showed the human Ubc9(C93S) mutant is severely 
compromised in its interaction with SUMO-1 but can still 
interact with its SUMOylation target, the AP-2 transcription 
factor, as efficiently as wild type UBC9, leading the authors to 
suggest a dominant negative mechanism.79 Similarly, because 
free SUMO levels are reported to be limiting in cells,78 it pos-
sible that, when overexpressed alone, wild type UBC-9 binds to 
a greater number of its protein targets but lacks sufficient free 
SUMO to SUMOylate those proteins efficiently, resulting in a 
similar dominant negative effect. Further supporting this pos-
sibility, we also found that UBC-9 and SMO-1 co-expression 
in GABAergic neurons caused non-additive increases in mus-
cle contraction (Figure 6b), indicating these proteins likely 
exert their effects on NMJ function through a common path-
way, which would be expected to involve SUMOylation. Our 
additional observation that neuronal knockdown or GABAergic 
neuron overexpression of the E1 SUMO-activating enzyme 
subunit AOS-1 also resulted in increased muscle contraction, 
synaptic vesicle accumulation, and PTZ sensitivity (Figures 1–
4) further indicates that the expression and activity of multiple 
SUMO enzymes must be precisely regulated for proper NMJ 
function. Because the Aos1-Uba2 heterodimeric E1 enzyme 
must bind Ubc9 to enforce SUMO transfer to the E2,32 the 
UBC-9 and AOS-1 overexpression phenotypes in our system 
also could be due to an imbalance in UBC-9:AOS-1-UBA-2 
stoichiometry again leading to dominant negative-type sub-
strate sequestration effects. Together, while SUMOylation-
independent effects of UBC-9 have been previously 
demonstrated84–87 and cannot fully be ruled out, these data 
suggest the phenotypes seen with wild type UBC-9 overex-
pression in our study are most likely due to SUMO-limiting 
effects and/or incorrect stoichiometry of SUMO pathway 
enzymes rather than indicating an endogenous non-catalytic 
UBC-9 function at this synapse.
When considering our data in light of a model involving 
UBC-9’s SUMOylation activity, it appears that either too 
much or too little SUMOylation can lead to increased muscle 
excitation. Too little SUMOylation could be occurring in the 
case of ubc-9 knockdown and in the case of UBC-9 or UBC-
9(C93S) expression alone through the dominant negative and 
substrate sequestration mechanisms discussed above. 
Conversely, if UBC-9 acts in a common pathway with SMO-1 
when the 2 are overexpressed together, it is likely due to excess 
SUMOylation, since conjugation-independent effects of 
SMO-1 and UBC-9 would not necessarily be expected to 
depend on one another. Previous work in C. elegans showed 
that although muscle-specific overexpression of the non-con-
jugatable SMO-1(GA) or human SUMO-2(GA) caused some 
defects in C. elegans body morphology, these were less severe 
than the defects seen with wild type SMO-1 or SUMO-1 
overexpression.45 This suggests the majority of effects of 
SMO-1 overexpression result from increased target 
SUMOylation, which has been detected with SUMO overex-
pression in other systems,78 rather than non-specific or indirect 
effects. Other studies described additional cases in which either 
the excess or absence of synaptic protein SUMOylation causes 
similar defects in synapse formation or function. For example, 
SUMOylation of the active zone protein, Rim1α, is required 
for action potential-evoked synaptic vesicle exocytosis and cal-
cium entry, whereas non-SUMOylated Rim1α aids in synaptic 
vesicle docking and priming. Thus, either too much or too little 
Rim1α SUMOylation can decrease synaptic vesicle release.10 
Likewise, SUMOylated syntaxin1A slows endocytosis, gener-
ally under intense stimulation, while non-SUMOylated syn-
taxin1A is a critical part of the SNARE complex required for 
membrane fusion during exocytosis.9 As our experiments 
focused on steady state neuromuscular activity in adult organ-
isms rather than muscle excitation achieved under specific 
stimulation conditions, it is possible subtle differences in the 
nature of the defects caused by excess or reduced SUMOylation, 
if both occurred in our system, all manifested as increased mus-
cle excitation. Future studies examining the SUMOylation lev-
els of specific proteins in GABAergic neurons under 
knockdown and overexpression conditions and using electro-
physiology or calcium imaging to more directly measure syn-
aptic transmission will be needed to fully delineate the 
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mechanisms by which UBC-1 and SMO-1 affect muscle 
excitation.
UBC-9 can control GABAergic vesicle localization 
potentially through local presynaptic effects
Although we did not explore specific SUMOylation targets in 
this study, our imaging data provide some clues as to the poten-
tial mechanism by which UBC-9 misexpression impacts 
GABAergic signaling to control E:I balance. Using quantita-
tive imaging of GFP::SNB-1, we found worms with panneu-
ronal or GABAergic neuron-specific UBC-9 overexpression 
accumulated synaptic vesicles relative to wild type worms in 
GABAergic but not in cholinergic motor neurons (Figure 3a). 
Increased GFP::SNB-1 puncta intensity typically reflects 
decreased exocytosis of vesicles into the synaptic cleft and cor-
relates with decreased signaling.48–50 Conversely, increased 
interpunctal fluorescence often coincides with endocytic 
defects, as this fluorescence is indicative of GFP::SNB-1-
containing vesicles that have fused with the membrane, allow-
ing the GFP::SNB-1 to diffuse away from the synapse.49 The 
fact that we observed increases in both punctal and interpunc-
tal GFP::SNB-1 fluorescence could indicate that the UBC-9 
overexpressing animals actually have increased release and/or 
increased levels of GABA-containing vesicles. Alternatively, it 
is possible UBC-9 overexpression affects aspects of both syn-
aptic vesicle exo- and endocytosis. While we cannot exclude 
either of these possibilities, or more complicated multicellular 
effects on both cholinergic and GABAergic signaling, a net 
decrease in GABA release is most consistent with the increased 
muscle contraction and the GABA-dependent seizure behav-
iors we observed in the aldicarb and PTZ assays, respectively, 
following UBC-9 overexpression (Figures 2 and 4). Accordingly, 
as loss of function of either the calcium channel subunit 
UNC-2 or the anaphase-promoting complex ubiquitin ligase, 
both of which are required for synaptic vesicle release from 
motor neurons, exhibit similar increases in both GFP::SNB-1 
punctal and interpunctal fluorescence,48,88 it is possible the 
increases we observed in UBC-9 overexpressing animals 
resulted from synaptic vesicle buildup that led to spillover 
beyond synaptic sites. Such spillover may or may not be due to 
overall increases in the total number of vesicles and/or to 
defects in vesicle trafficking or maintenance at synapses.48
Importantly, these presynaptic effects may be accompanied 
by postsynaptic changes in GABA receptor levels or sensitivity, 
as mutants lacking UNC-49 GABAA receptors are both 
aldicarb hypersensitive and exhibit PTZ-induced convul-
sions.50,72 Increases in GABAA receptors have been observed in 
response to decreased GABA release in C. elegans lacking the 
function of the anaphase promoting complex, and the opposing 
homeostatic responses to increases in GABA release have been 
reported in other systems.48,89 While it is possible increased 
GABA release could be leading to decreased GABA receptor 
expression or sensitivity (or vice versa, if there are cell non-
autonomous effects of our neuronally expressed SUMO 
enzymes) to cause the behavioral responses we observe, such 
changes would be expected to maintain relatively wild type lev-
els of GABAergic signaling. Thus, while further exploration of 
the homeostatic effects of neuronal UBC-9 overexpression on 
muscle excitation, as well as additional roles for SUMO 
enzymes within the muscle cells themselves, will be of interest 
to explore, our current data most directly support a presynaptic 
role for the overexpression effects.
Not only do our data suggest UBC-9 expression levels criti-
cally regulate synaptic vesicle localization and potentially 
release, but by imaging worms co-expressing GFP::UBC-9 or 
GFP::SMO-1 with mCherry::SNB-1 in GABAergic neurons, 
we observed strong localization of UBC-9 and SMO-1 at pre-
synaptic sites (Figure 4). Given that we also observe 
GFP::UBC-9 and GFP::SMO-1 in the cell bodies (data not 
shown), as well as at synapses and more diffusely along the 
dorsal and ventral nerve cords, our results do not preclude the 
function of overexpressed UBC-9 in the nucleus or elsewhere 
within the motor neurons in this context. However, the fact 
that UBC-9 and SMO-1 can localize to synapses is consistent 
with a model in which UBC-9 and SMO-1 regulate overall 
neuromuscular activity and synaptic vesicles in GABAergic 
neurons by acting directly at presynaptic sites through effects 
on synaptic proteins. This model is supported by prior studies 
demonstrating stimulation-dependent localization of mamma-
lian Aos1, Ubc9, as well as other SUMOylation and deSU-
MOylation machinery, to hippocampal presynaptic sites, where 
increased SUMOylation of synaptic proteins and effects on 
synaptic vesicle release are also observed.14,15,25 In hippocampal 
spines, activity-dependent Ubc9 localization occurs in response 
to an increase in its Protein Kinase C (PKC)-phosphorylated 
substrates and is dependent upon its catalytic cysteine.13 It will 
be of interest to determine whether activity-dependent locali-
zation of C. elegans SUMOylation machinery to GABAergic 
presynapses also occurs and what domains are required for this 
localization. Mammalian Ubc9 is also known to be regulated 
by acetylation and SUMOylation, modifications that can alter 
its substrate specificity and thus potentially its localization.30,90 
Whether C. elegans UBC-9 is similarly regulated remains to be 
explored.
As noted above, work done at glutamatergic synapses in 
other systems uncovered several SUMOylated presynaptic 
proteins, including Rim1α, synaptotagmin-1, synapsin1A, 
and syntaxin1A, which could mediate the effects of UBC-9 at 
GABAergic presynapses to regulate synaptic vesicle release, 
supporting the relevance of UBC-9 activity to synaptic plas-
ticity9,10,27,28 and to learning and memory.37 Defects in synap-
tic protein SUMOylation are also linked to neurological and 
neurodegenerative diseases in which E:I imbalances occur.16,91 
For example, the A548T mutation in synapsin1A, which is 
strongly associated with autism and epilepsy,91 causes reduced 
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synapsin1A SUMOylation leading to a reduction in the 
releasable synaptic vesicle pool following neuronal stimulation 
in mouse hippocampal neuron cultures. It will be of interest to 
determine whether the defects in vesicle exocytosis due to loss 
of synapsin1A SUMOylation contribute to the disease phe-
notype in patients with the A548T mutation and whether 
SUMOylation of synapsin1A or other synaptic vesicle-associ-
ated proteins is critical for transmission at GABAergic 
synapses.
Conclusions and Future Directions
Overall, our data are consistent with a role for the SUMO 
pathway, and specifically, the SUMO-conjugating enzyme 
UBC-9, in promoting E:I balance at the C. elegans NMJ by 
acting locally at presynaptic sites in GABA neurons to control 
GABAergic signaling to prevent excess muscle excitation. 
Although additional studies are required to determine the pre-
cise mechanism underlying UBC-9 and other SUMO enzyme 
effects at this synapse, to our knowledge, this work is the first 
to demonstrate presynaptic function and localization of both 
UBC-9 and SMO-1 at inhibitory GABAergic synapses in any 
organism. It also further supports the increasingly prevalent 
notion that tight regulation of the SUMO enzyme system is 
critical for E:I balance within the nervous system. Given that 
AOS-1 overexpression causes similar effects to that seen with 
UBC-9, additional investigation into the effects of other 
SUMOylating and de-SUMOylating enzymes will be of inter-
est to ascertain the full extent of SUMO pathway influence at 
the NMJ. Future studies identifying targets of SUMO-
dependent and/or independent functions of UBC-9 at this 
synapse, associated E3 SUMO ligases and/or deubiquitinating 
enzymes, and potential regulation of UBC-9 and other SUMO 
pathway components by activity, oxidative stress, and hormone 
signaling, all of which can impact neuronal SUMOylation,16,53,92 
will be critical for understanding how UBC-9 regulates pre-
synaptic function in GABAergic neurons. Such studies will 
inform further investigation into the roles Ubc9 and the 
SUMO system play in mammalian GABAergic neurons and, 
in so doing, will contribute to our understanding of E:I balance 
misregulation in neurological and neurodegenerative diseases 
in which the SUMO pathway is disrupted.
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